Royal Bank Of Canada Forecasts Strong Price Appreciation for Teleflex (NYSE:TFX) Stock

Teleflex (NYSE:TFX) had its price objective boosted by analysts at Royal Bank Of Canada from $115.00 to $125.00 in a report released on Friday,Benzinga reports. The firm currently has a “sector perform” rating on the medical technology company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 2.50% from the stock’s previous close.

Several other research firms have also commented on TFX. Wells Fargo & Company boosted their price objective on Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a research note on Friday. Needham & Company LLC lifted their price target on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Truist Financial raised their price objective on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a report on Thursday, December 18th. Finally, Wall Street Zen lowered shares of Teleflex from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Teleflex currently has an average rating of “Hold” and an average price target of $140.71.

Teleflex Price Performance

Shares of NYSE TFX opened at $121.95 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 2.57. The firm has a fifty day moving average of $111.34 and a 200 day moving average of $118.71. The firm has a market cap of $5.39 billion, a PE ratio of -5.93, a PEG ratio of 1.59 and a beta of 0.92. Teleflex has a one year low of $100.18 and a one year high of $143.32.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.73 by ($1.80). The company had revenue of $569.00 million during the quarter, compared to analyst estimates of $912.57 million. Teleflex had a negative net margin of 30.56% and a positive return on equity of 13.48%. The firm’s revenue for the quarter was down 28.5% compared to the same quarter last year. During the same quarter last year, the business earned $3.89 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts predict that Teleflex will post 13.98 EPS for the current fiscal year.

Institutional Trading of Teleflex

Several hedge funds have recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Teleflex by 57.9% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. Banque Cantonale Vaudoise lifted its stake in Teleflex by 82.5% during the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 113 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in Teleflex by 248.8% in the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after purchasing an additional 199 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Teleflex in the third quarter valued at approximately $35,000. Finally, True Wealth Design LLC increased its stake in Teleflex by 10,333.3% in the second quarter. True Wealth Design LLC now owns 313 shares of the medical technology company’s stock valued at $37,000 after purchasing an additional 310 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Wells Fargo raised its price target to $130 (from $116) and maintained an “equal weight” rating — a near-term bullish signal that can support buying interest. Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $125 (from $115) with a “sector perform” rating — another analyst lift that helps underpin the rally. Read More.
• Positive Sentiment: Teleflex’s board declared a quarterly cash dividend of $0.34 per share (record date March 6, payable March 31), which can attract income-seeking investors and provide support. Read More.
• Positive Sentiment: The company launched a multi‑year restructuring tied to planned divestitures — investors appear to view this as steps to simplify the portfolio, cut costs and potentially unlock value. Read More.
• Neutral Sentiment: Teleflex published its Q4 presentation and full-year results (material and earnings‑call transcripts are available) — useful for modeling but not a driver by itself. Read More.
• Negative Sentiment: Q4 results missed materially: EPS $1.93 vs. consensus ~$3.73 and revenue $569M vs. ~$912.6M — revenue fell ~28.5% year-over-year and margins contracted, a clear near-term negative for earnings momentum. Read More.
• Negative Sentiment: FY‑2026 guidance was significantly reduced: EPS guidance of $6.25–$6.55 and revenue guidance around $2.3B vs. street expectations materially higher (~$15 EPS and ~$3.7B revenue), which is a major downward re‑rating of near-term expectations. Read More.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.